The Cancer Cell Biology Program seeks to enable new approaches to cancer pathogenesis and therapy by catalyzing interactions between DF/HCC scientists and clinicians. The overarching goal is to facilitate """"""""""""""""bench-to-bedside"""""""" collaborations, bringing basic discoveries into the clinic, and """"""""bedside-to-bench"""""""" collaborations, when a deep knowledge of the clinical features of a particular disease helps drive fundamental discovery of pathogenesis mechanisms, ultimately leading to new treatment strategies.
The specific aims of the Cancer Cell Biology Program are to: 1) exploit emerging technologies to elucidate the cellular mechanisms that underlie tumorigenesis;and 2) leverage basic science discoveries to inspire pre-clinical and clinical development of novel therapeutics. The 99 members of this Program are unified through their use of molecular, biochemical, and cell biological approaches to delineate and alter cancer cell behavior. They represent all DF/HCC institutions. In 2009, members received more than a total of $79.3 million in overall grant funding (TC), of which $22.1 million was from NCI and $42.5 million was from other peer-review sponsors. Members published 1,546 publications during the current project period (2006 to 2010), of which 5% were intra-programmatic, 26% were inter-programmatic, and 20% were inter-institutional. Inter- and intra-programmatic collaborations have not only led to the development of novel therapeutics, but have also inspired complementary avenues of basic scientific investigation. In the 2005 CCSG renewal, the program received an outstanding merit score. It is poised to continue that trajectory in the next project period.

Public Health Relevance

New technologies will accelerate the discovery of the mechanisms of tumorigenesis. The coordination of discovery-oriented basic cancer research with efforts to identify and test new cancer drugs will continue to have significant impact on the care of cancer patients. With these interdisciplinary approaches in place, the results of clinical trials can, in turn, refine basic cell biology discovery efforts;ultimately leading to more targeted and individualized therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601455
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$76,207
Indirect Cost
$60,778
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications